JP2018518454A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518454A5
JP2018518454A5 JP2017552082A JP2017552082A JP2018518454A5 JP 2018518454 A5 JP2018518454 A5 JP 2018518454A5 JP 2017552082 A JP2017552082 A JP 2017552082A JP 2017552082 A JP2017552082 A JP 2017552082A JP 2018518454 A5 JP2018518454 A5 JP 2018518454A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
seq
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518454A (ja
JP6901400B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/025802 external-priority patent/WO2016161410A2/en
Publication of JP2018518454A publication Critical patent/JP2018518454A/ja
Publication of JP2018518454A5 publication Critical patent/JP2018518454A5/ja
Priority to JP2021100601A priority Critical patent/JP7242760B2/ja
Application granted granted Critical
Publication of JP6901400B2 publication Critical patent/JP6901400B2/ja
Priority to JP2023035685A priority patent/JP2023063377A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552082A 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法 Expired - Fee Related JP6901400B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021100601A JP7242760B2 (ja) 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法
JP2023035685A JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562143016P 2015-04-03 2015-04-03
US62/143,016 2015-04-03
US201562191797P 2015-07-13 2015-07-13
US62/191,797 2015-07-13
PCT/US2016/025802 WO2016161410A2 (en) 2015-04-03 2016-04-03 Treatment of cancer using inhibitors of tgf-beta and pd-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021100601A Division JP7242760B2 (ja) 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Publications (3)

Publication Number Publication Date
JP2018518454A JP2018518454A (ja) 2018-07-12
JP2018518454A5 true JP2018518454A5 (https=) 2019-05-16
JP6901400B2 JP6901400B2 (ja) 2021-07-14

Family

ID=56920908

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552082A Expired - Fee Related JP6901400B2 (ja) 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法
JP2021100601A Active JP7242760B2 (ja) 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021100601A Active JP7242760B2 (ja) 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Country Status (6)

Country Link
US (4) US10167334B2 (https=)
EP (2) EP3770171A1 (https=)
JP (3) JP6901400B2 (https=)
CN (2) CN116327915A (https=)
ES (1) ES2820768T3 (https=)
WO (1) WO2016161410A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
MX394957B (es) * 2015-09-03 2025-03-24 Ono Pharmaceutical Co Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
EP3779447B1 (en) 2016-03-15 2023-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to activate the anti-tumoral cd8+t cell response of a patient affected with a cancer
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
EP3571227A1 (en) * 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
TWI788321B (zh) 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634437A4 (en) 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CA3084581A1 (en) 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019136320A1 (en) 2018-01-05 2019-07-11 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
JP2021518413A (ja) * 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN112512576A (zh) * 2018-05-04 2021-03-16 默克专利有限公司 PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
CN112638403A (zh) * 2018-07-03 2021-04-09 康泰伦特药物解决方案有限责任公司 包括饰胶蛋白聚糖的多功能蛋白质分子及其用途
US11359024B2 (en) 2018-09-07 2022-06-14 Pfizer Inc. Anti-AVB8 antibodies and compositions and uses thereof
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
US20210340240A1 (en) * 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
US20210396737A1 (en) * 2018-11-21 2021-12-23 Highlight Therapeutics, S.L. Nanoplexed poly(i:c) formulations and uses thereof
WO2020146345A1 (en) * 2019-01-07 2020-07-16 Children's Medical Center Corporation Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
WO2020248908A1 (zh) * 2019-06-10 2020-12-17 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN110464841B (zh) * 2019-08-19 2020-05-22 启辰生生物科技(珠海)有限公司 免疫增强的药物组合物及其应用
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
US11802145B2 (en) 2019-10-21 2023-10-31 Nanjing Leads Biolabs Co., Ltd. Recombinant protein targeting PD-1 and TGFß
EP4051279A1 (en) * 2019-11-01 2022-09-07 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
MX2022007759A (es) * 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230072133A1 (en) * 2020-02-25 2023-03-09 WuXi Biologics Ireland Limited A bifunctional fusion protein and uses thereof
US20230235057A1 (en) * 2020-04-29 2023-07-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bifunctional protein against pd-1 and tgf-beta
JP7419168B2 (ja) * 2020-06-10 2024-01-22 株式会社東芝 改変型piggyBacトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
TW202330626A (zh) * 2021-09-30 2023-08-01 大陸商貝達藥業股份有限公司 雙特異性抗體及其應用
KR102763607B1 (ko) * 2021-10-05 2025-02-07 주식회사 인게니움테라퓨틱스 자연살해 세포의 활성 향상용 조성물
CN121466307A (zh) * 2022-04-01 2026-02-06 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7369111B2 (en) 2003-04-29 2008-05-06 Samsung Electronics Co., Ltd. Gate driving circuit and display apparatus having the same
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN101084007A (zh) 2004-09-22 2007-12-05 金齐姆公司 TGF-β拮抗剂限制免疫抑制剂肾毒性的用途
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
JP2009521496A (ja) 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー TGF−β結合組成物
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
SG195253A1 (en) * 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1

Similar Documents

Publication Publication Date Title
JP2018518454A5 (https=)
JP2021155431A5 (https=)
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
RU2695332C2 (ru) Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
CN110536905B (zh) 用于治疗肺癌的抗pd-1抗体
JP2019515008A5 (https=)
JP2019519499A5 (https=)
JP2017533912A5 (https=)
JP2020504141A5 (https=)
JP2020503364A5 (https=)
JP2020508317A5 (https=)
CN108473578A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
JP2020514310A5 (https=)
JP7797875B2 (ja) 癌の治療及び/又は予防のための医薬品
JP2018503365A5 (https=)
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
BR122023025321A2 (pt) Uso de anticorpos anti-b7-h1 e anti-ctla-4
JP2020527332A5 (https=)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2015532292A5 (https=)
JP2021511372A5 (https=)
JP2021523170A5 (https=)
JP2018512402A5 (https=)
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
AU2021378793B2 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer